Like many neurodegenerative diseases, the clinical symptoms of Parkinsons disease (PD) do not manifest until significant progression of the disease has already taken place, motivating the need for sensitive biomarkers of the disease. While structural imaging is a potentially attractive method due to its widespread availability and non-invasive nature, global morphometric measures (e.g., volume)...

Home based objective measures of bradykinesia and dyskinesia will be important in managing Parkinsons Disease (PD). The Aim of this paper was to further validate the Parkinsons Kinetigraph system as a tool for measuring bradykinesia and dyskinesia by examining its capacity capture the effect of therapeutic interventions, detect bradykinesia and asymmetry in a newly diagnosed patients, and corre...

BACKGROUND Epidemiological data concerning the prevalence of major depression in PD patients in Belgium is very scarce. METHODS A total of 1086 patients with idiopathic Parkinsons disease were included in the analysis. The neurological evaluation of the patients was made by the Hoehn and Yahr Staging of Parkinsons disease, the Unified Parkinson Disease Rating Scale (UPDRS), and the Schwab and...

The vision behind our project is a closed-loop system for continuous deep brain stimulation (DBS) based on features extracted from complex motion data. Our focus is on Parkinsons Disease (PD) patients, with a possible expansion to related neurological disorders. The system we envision is lightweight, will continuously gather motion information, will automatically extract high-level features fro...

Parkinson's, a progressive neural disorder, is difficult to identify due to the hidden nature of the symptoms associated. We present a machine learning approach that uses a definite set of features obtained from the Parkinsons Progression Markers Initiative(PPMI) study as input and classifies them into one of two classes: PD(Parkinson's disease) and HC(Healthy Control). As far as we know this i...

Ambulatory monitoring of motor symptoms in Parkinsons disease (PD) can improve our therapeutic strategies, especially in patients with motor fluctuations. Previously published monitors usually assess only one or a few basic aspects of the cardinal motor symptoms in a laboratory setting. We developed a novel ambulatory monitoring system that provides a complete motor assessment by simultaneously...

4753 See also Altruism and Prosocial Behavior, Sociology of; Cultural Buy Theory and Models; Ethics and Values; Evolutionary Theory and Education; Natural Selection; Buy binary option Charles City Development EthoDiscount binary options strategies Turlock and Evolutionary Approaches; Value Pluralism; Values. Oxford Oxford Science Publications. Introduction The most common treatment for Parkinso...

BACKGROUND/AIM Selective serotonin reuptake inhibitors are the most commonly chosen antidepressants in patients with Parkinson's disease (PD). The aim of our study was to assess the influence of fluoxetine (Flu) on motor functions in patients with PD. METHODS In this prospective, controlled, open-label study, 18 patients with PD and mild depression [(10 < or = Hamilton Rating Scale for Depres...

Technology and target group: In Parkinsons disease, the brain cells that produce dopamine die. Approximately 15 000 patients in Sweden have Parkinsons disease. In its early stages, the disease can often be treated successfully by drugs. However, in most patients the disease progresses after a few years to a stage with complications where drugs no longer have a sufficient effect. In patients wit...

Swallowing difficulties and constipation were included in the first description of Parkinsons ́s syndrome from 1817 (Parkinson 1817). Since then, numerous studies have confirmed the magnitude of symptoms and addressed their pathophysiology. In spite of this, much remains to be determined and treatment of gastrointestinal dysfunction in Parkinson ́s disease (PD) is often unsatisfactory. Parkinson ́...